ASCRS This Week - November 2, 2022

ASCRS Consensus Statement on VUITY

With the voluntary update of prescribing information for the topical presbyopia treatment VUITY (pilocarpine hydrochloride ophthalmic solution) 1.25% by Allergan, an ASCRS Task Force convened and developed a consensus statement on the preliminary understanding of the data and the appropriate counseling of patients.

The ASCRS Consensus Statement on VUITY:

Provides an overview of the additions Allergan made to the Prescribing Information;
Presents a summary of the FDA registration study findings;
Reviews the literature regarding postmarket experience with VUITY; and
Summarizes the ASCRS Task Force recommendations.

Read the full ASCRS Consensus Statement of VUITY.

Nominating Committee Accepting Submissions for Executive Board Position

ASCRS is accepting nominations for candidates for Secretary on the ASCRS Executive Board in 2023. This position will have succession responsibilities, including Treasurer, Incoming President, and ultimately 2026 President.

Criteria for consideration of an ASCRS Executive Board member include:

Member in good standing of ASCRS and service to ASCRS
Contributions to scholarly research
Presentations at national/international meetings
Teaching activities
Leadership qualities
Clinical/surgical expertise and reputation
Industry/corporate relations/collaborations

To nominate an ophthalmologist for the position of Secretary on the ASCRS Executive Board, please send an email to [email protected] by November 27, describing how the nominee fits the above criteria and why you are recommending them for this position. A CV may also be attached. Nominations can be for yourself or another member. Per the ASCRS Bylaws, the Nominating Committee will review submissions and present their recommendation(s) to the Executive Board.

Perspectives on Private Equity in Ophthalmology

The latest episode of the YES Connect Webinar series features “Perspectives on Private Equity in Ophthalmology.” While this webinar series is designed specifically for young eye surgeons, it is applicable for ophthalmologists at any age.

The episode on private equity features Albert Cheung, MD, Ashleigh Levison, MD, Thomas Meirick, MD, Ben Nicholas, MD, and Kavitha Sivaraman, MD. Find the episode and all YES Connect Webinars here.

EyeWorld Spotlight

Research out of Wayne State University turned to “drug repurposing” to identify already-approved therapies that could be used to treat antibiotic-resistant bacterial infections in the eye.

Read this EyeWorld Spotlight for more insights about the research.